$33.05
−7.89%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$34.89
From 52W high−39.99%
Volume149343.00
Market cap$1.68B
P/E (TTM)—
P/S (TTM)49.4x
Div yield—
Key dataSep 18, 2026
Open
$34.89
From 52W high
−39.99%
Volume
149343.00
Market cap
$1.68B
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−124.8x
P/E (TTM)
—
RSI (14)
38.9
MomentumView details →
1D Return
−7.89%
YTD Return
+47.92%
SummaryUpdated Dec 1, 2025
Nanobiotix S.A. (NASDAQ:NBTX) is a clinical-stage biotechnology company founded in 2003 and headquartered in Paris, France. The company went public on NASDAQ in December 2020. Nanobiotix specializes in developing nanotechnology-based therapeutic solutions for cancer treatment, with its lead product candidate NBTXR3 currently in advanced clinical trials. The company has established significant partnerships, most notably a global licensing agreement with Johnson & Johnson worth potentially over $2.5 billion, marking a major validation of its nanotechnology platform approach to oncology.
Similar companies
Latest newsMore news →
Nanobiotix announced complete full-cohort Phase 1 results for JNJ-1900 (NBTXR3) in inoperable, recurrent non-small cell lung cancer, presented at the IASLC 2026 World Conference on Lung Cancer.6d agoNanobiotix provided an operational update and reported financial results for the first quarter of 2026.110d ago